
CLOV Stock Forecast & Price Target
CLOV Analyst Ratings
Bulls say
Clover Health Investments Corp has demonstrated a significant upward trajectory in its Medicare Advantage membership, achieving a remarkable 53% growth during the recent annual enrollment period, which positions the company well with approximately 153,000 members for the 2026 plan year. Furthermore, Clover's expectations for enhanced new member revenue, projected to exceed $70 per member per month, and the anticipated benefits of being recognized as a 4-star plan in 2026 suggest a robust improvement in contribution margins, driven by improved health documentation and higher retention rates. Finally, the company's strategic focus on adopting its proprietary Clover Assistant technology continues to enhance medical cost ratios, ultimately contributing to better unit economics and margin contributions as these new cohorts mature through 2027 and beyond.
Bears say
Clover Health Investments Corp is facing a negative outlook primarily due to the projected decline in gross profit margins, which is anticipated as a result of absorbing new members with lower profitability. The company's inability to retain a 4-Star rating has raised concerns about potential impacts on future Medical Loss Ratios (MLR) and earnings, which could lead to negative revisions in consensus forecasts. Additionally, various risks such as regulatory changes, adverse-selection due to market exits by larger peers, and increased competition in the Medicare Advantage space contribute to uncertainties in Clover's financial outlook.
This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.
CLOV Analyst Forecast & Price Prediction
Start investing in CLOV
Order type
Buy in
Order amount
Est. shares
0 shares